101 related articles for article (PubMed ID: 1764273)
1. Trofosfamide in non-Hodgkin's lymphoma. A phase II study.
Wist E; Risberg T
Acta Oncol; 1991; 30(7):819-21. PubMed ID: 1764273
[TBL] [Abstract][Full Text] [Related]
2. Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study.
Helsing MD
Eur J Cancer; 1997 Mar; 33(3):500-2. PubMed ID: 9155539
[TBL] [Abstract][Full Text] [Related]
3. Palliative chemotherapy in non-Hodgkin's lymphoma.
Salminen E; Nikkanen V; Lindholm L
Oncology; 1997; 54(2):108-11. PubMed ID: 9075780
[TBL] [Abstract][Full Text] [Related]
4. Complete remission after repeated trofosfamide treatment in relapsing high-grade malignant non-Hodgkin's lymphoma--a case report.
Norum J
Acta Oncol; 1994; 33(7):831. PubMed ID: 7993654
[No Abstract] [Full Text] [Related]
5. Trofosfamide is effective in refractory non-Hodgkin's lymphoma.
Salminen E; Nikkanen V; Lindholm L
Eur J Cancer; 1995 Dec; 31A(13-14):2419-20. PubMed ID: 8652284
[No Abstract] [Full Text] [Related]
6. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
[TBL] [Abstract][Full Text] [Related]
7. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Chisesi T
Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
[TBL] [Abstract][Full Text] [Related]
8. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Baldini L; Guffanti A; Gobbi P; Colombi M; Federico M; Avanzini P; Cavanna L; Pieresca C; Silingardi V; Maiolo AT
Cancer; 1997 Mar; 79(6):1234-40. PubMed ID: 9070503
[TBL] [Abstract][Full Text] [Related]
9. [Ixoten therapy in malignant lymphomas].
Pötzi P; Aiginger P; Kühböck J
Acta Med Austriaca; 1979; 6(5):247-9. PubMed ID: 400215
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group.
Andersen J; Thorling K; Bentzen SM; Brincker H; Christensen BE; Pedersen M
Acta Oncol; 1990; 29(8):995-9. PubMed ID: 1703769
[TBL] [Abstract][Full Text] [Related]
12. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
Lichtman SM; Petroni G; Schilsky RL; Johnson JL; Perri RT; Niedzwiecki D; Sklar J; Barcos M; Peterson BA
Leuk Lymphoma; 2001; 42(6):1255-64. PubMed ID: 11911406
[TBL] [Abstract][Full Text] [Related]
13. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
14. Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients.
Morgenfeld MC; Pavlovsky A; Suarez A; Somoza N; Pavlovsky S; Palau M; Barros CA
Cancer; 1975 Oct; 36(4):1241-9. PubMed ID: 1100220
[TBL] [Abstract][Full Text] [Related]
15. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma.
Liliemark J; Martinsson U; Cavallin-Ståhl E; Svedmyr E; Porwit A; Strömberg M; Juliusson G
Leuk Lymphoma; 1998 Aug; 30(5-6):573-81. PubMed ID: 9711919
[TBL] [Abstract][Full Text] [Related]
16. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
17. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
[TBL] [Abstract][Full Text] [Related]
18. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M
J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721
[TBL] [Abstract][Full Text] [Related]
20. High-dose cyclophosphamide followed by autografting can improve the outcome of relapsed or resistant non-Hodgkin's lymphomas with involved or hypoplastic bone marrow.
Santini G; De Souza C; Congiu AM; Nati S; Marino G; Soracco M; Sertoli MR; Rubagotti A; Spriano M; Vassallo F; Rossi E; Vimercati R; Piaggio G; Figari O; Benvenuto F; Abate M; Truini M; Ravetti JL; Ribizzi I; Damasio E
Leuk Lymphoma; 1999 Apr; 33(3-4):321-30. PubMed ID: 10221512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
